At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 26 enrolled
Drug / intervention
LY3502970 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multiple Dose Study in Healthy Participants to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3502970
In Brief
A Phase 1 clinical trial evaluating LY3502970 and Esomeprazole for Healthy. Completed, enrolled 26 participants across 1 site.
Detailed Summary
The main purpose of this study is to assess how fast LY3502970 gets into the blood stream and how long it takes the body to remove it when administered in multiple oral doses as new formulation compared to that of reference LY3502970 formulation. Information about safety and tolerability will be collected. The study is open to healthy participants. The study is conducted in two parts and it will last up to about 6 months, inclusive of screening period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited Kingdom
CollaboratorsQuotient Sciences
Timeline
Phase 1CompletedFinished
20222023202420252026
Enrollment StartSep 2021
First PostedSep 2021
Primary CompletionApr 2022
TodayJul 2026
First PostedSep 21, 2021
Enrollment StartSep 16, 2021
Primary CompletionApr 4, 2022
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 4.8 years ago
Interventions
LY3502970drug
Administered orally.
Esomeprazoledrug
Administered orally.